Novocure Ltd (NVCR)

[deadboy]

Motley Fool says today is only the begining.

Here's Why NovoCure Ltd. Is Skyrocketing Today

Now what

While NovoCure has consistently posted triple-digit top-line growth over the last few quarters, its stock has been a dreadful long-term performer. In fact, it has badly trailed the medical device industry in general as measured by the iShares US Medical Devices ETF (NYSEMKT:IHI) since its October 2015 IPO.

Thankfully, the data from all of these clinical trials suggest that Optune holds the potential to have a transformative impact on the way that we treat numerous types of cancers. Given that tens of thousands of patients die from ovarian, pancreatic, solid tumor, and brain cancer each year in the U.S. alone, the potential growth runway for Optune continues to look massive. For perspective, only 1,091 patients worldwide were actively using Optune as of the end of 2016.

Looking ahead, the uplifting data from the EF-14 trial should make it easier for the company to convince providers, patients, and insurers to use and cover Optune. That would allow the company's torrid top-line growth rate to continue. Meanwhile, the data from the Panova, Stellar, and Innovate trials suggest that NovoCure's plans to expand Optune's labeling to other types of cancer could also work out. If true, then it is possible that today's big jump could just be the start of a profitable long-term run.